Warfarin Dose Adjustment Recommendation
Increase the weekly warfarin dose by approximately 10-20% (1-2 mg weekly), bringing the total weekly dose to 10-11 mg, then recheck INR in 3-7 days.
Rationale for Dose Adjustment
With a current INR of 1.4 on 9 mg weekly (approximately 1.3 mg daily), this patient is significantly below the therapeutic target of 2.0-3.0. The FDA labeling emphasizes individualized dosing based on INR response 1, and standard practice supports adjusting the total weekly dose by 5-20% when INR values are out of range 2.
Specific Dosing Algorithm
For an INR of 1.4 (substantially subtherapeutic):
- Current dose: 9 mg/week
- Recommended increase: 10-20% of current dose = 0.9-1.8 mg
- New weekly dose: 10-11 mg/week (round to practical tablet strengths)
- Recheck INR: In 3-7 days initially, then adjust monitoring frequency based on stability
The more aggressive 20% increase (to 11 mg weekly) is justified here because the INR is markedly below target, and the patient faces ongoing thrombotic risk from inadequate anticoagulation 2.
Clinical Context and Monitoring
The FDA labeling clearly states that warfarin dosing must be individualized according to INR response, with the goal of maintaining INR 2.0-3.0 for most indications including VTE, atrial fibrillation, and post-MI thromboprophylaxis 1. An INR of 1.4 provides inadequate protection against thromboembolism, which carries significant morbidity and mortality risk.
Key monitoring points:
- After dose adjustment, check INR 2-4 times weekly initially until stable 2
- Once therapeutic and stable, can extend to weekly, then eventually every 4-6 weeks 2
- Avoid single large dose adjustments; incremental weekly dose changes are safer
Important Caveats
Do not simply skip doses or make erratic changes - the goal is steady-state adjustment of the weekly total dose. Most dose changes should alter the weekly dose by 5-20%, not more 2.
Consider contributing factors before adjusting:
- Recent dietary vitamin K intake changes
- New medications (particularly antibiotics, antifungals, NSAIDs)
- Missed doses or compliance issues
- Acute illness affecting absorption or metabolism
Avoid overreaction to a single out-of-range INR if only slightly off target, but an INR of 1.4 requires action given the substantial gap from therapeutic range 2.
The priority here is preventing thrombotic complications (stroke, PE, systemic embolism) which have higher immediate morbidity and mortality risk than the modest bleeding risk associated with therapeutic anticoagulation 1.